Arvinas (ARVN) Competitors $22.69 +1.05 (+4.85%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARVN vs. SNDX, PLRX, ANNX, MORF, ENTA, BPMC, NUVL, CYTK, VKTX, and LNTHShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Syndax Pharmaceuticals (SNDX), Pliant Therapeutics (PLRX), Annexon (ANNX), Morphic (MORF), Enanta Pharmaceuticals (ENTA), Blueprint Medicines (BPMC), Nuvalent (NUVL), Cytokinetics (CYTK), Viking Therapeutics (VKTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Syndax Pharmaceuticals Pliant Therapeutics Annexon Morphic Enanta Pharmaceuticals Blueprint Medicines Nuvalent Cytokinetics Viking Therapeutics Lantheus Syndax Pharmaceuticals (NASDAQ:SNDX) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Does the media prefer SNDX or ARVN? In the previous week, Syndax Pharmaceuticals had 16 more articles in the media than Arvinas. MarketBeat recorded 25 mentions for Syndax Pharmaceuticals and 9 mentions for Arvinas. Syndax Pharmaceuticals' average media sentiment score of 0.82 beat Arvinas' score of 0.32 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in SNDX or ARVN? Syndax Pharmaceuticals received 203 more outperform votes than Arvinas when rated by MarketBeat users. However, 66.67% of users gave Arvinas an outperform vote while only 65.48% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyndax PharmaceuticalsOutperform Votes38565.48% Underperform Votes20334.52% ArvinasOutperform Votes18266.67% Underperform Votes9133.33% Do insiders & institutionals have more ownership in SNDX or ARVN? 95.2% of Arvinas shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, SNDX or ARVN? Syndax Pharmaceuticals has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$139.71M9.75-$209.36M-$3.63-4.39Arvinas$78.50M19.86-$367.30M-$4.67-4.86 Which has more volatility & risk, SNDX or ARVN? Syndax Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Do analysts prefer SNDX or ARVN? Syndax Pharmaceuticals currently has a consensus price target of $37.18, indicating a potential upside of 133.11%. Arvinas has a consensus price target of $61.08, indicating a potential upside of 169.21%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Arvinas 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Is SNDX or ARVN more profitable? Arvinas' return on equity of -50.26% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax PharmaceuticalsN/A -64.34% -57.72% Arvinas N/A -50.26%-24.87% SummaryArvinas beats Syndax Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56B$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-4.865.5697.3414.18Price / Sales19.86348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book1.897.885.805.12Net Income-$367.30M$153.61M$119.07M$225.99M7 Day Performance-8.95%-2.00%-1.83%-1.32%1 Month Performance-11.92%-7.47%-3.64%0.60%1 Year Performance9.09%31.80%31.62%26.23% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.0807 of 5 stars$22.69+4.9%$61.08+169.2%+4.2%$1.56B$78.50M-4.86445Analyst ForecastShort Interest ↓SNDXSyndax Pharmaceuticals4.0038 of 5 stars$15.95+1.1%$37.18+133.1%+3.4%$1.35B$139.71M0.00110Analyst ForecastAnalyst RevisionPLRXPliant Therapeutics3.4806 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090ANNXAnnexon2.7706 of 5 stars$5.16-5.5%$15.80+206.2%+100.0%$550.00MN/A-5.0160Analyst RevisionMORFMorphic1.0513 of 5 stars$56.99flat$54.25-4.8%+136.6%$2.85B$520,000.00-16.28100ENTAEnanta Pharmaceuticals2.9547 of 5 stars$9.08-3.6%$20.00+120.3%+1.6%$192.41M$79.20M-1.73145BPMCBlueprint Medicines2.7079 of 5 stars$94.81+0.2%$122.11+28.8%+43.9%$6.02B$249.38M-44.93640Analyst ForecastNUVLNuvalent2.1677 of 5 stars$91.17+0.1%$112.60+23.5%+51.1%$5.90BN/A0.0040CYTKCytokinetics3.8052 of 5 stars$49.86-2.4%$83.67+67.8%+54.3%$5.88B$3.22M-9.27250Analyst ForecastInsider TradeOptions VolumeNews CoverageVKTXViking Therapeutics4.7706 of 5 stars$51.53+0.0%$109.80+113.1%+337.8%$5.74BN/A0.0020Analyst ForecastGap UpLNTHLantheus4.5262 of 5 stars$86.45+8.8%$122.50+41.7%+25.1%$5.52B$1.30B14.38834Positive NewsGap Up Related Companies and Tools Related Companies SNDX Competitors PLRX Competitors ANNX Competitors MORF Competitors ENTA Competitors BPMC Competitors NUVL Competitors CYTK Competitors VKTX Competitors LNTH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARVN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts